家事

Britain's Labour opposition has won 2 big prizes in special elections_我的网站

一 |     LONDON -- Britain's main opposition Labour Party has decisively won two special elections, snatching seats in Parliament that were long rock-solid bastions of the governing Conservatives.Results early Friday showed that voters in Tamworth, central England, and Mid-Bedfordshire, north of London, switched from Conservatives to Labour in almost unprecedented numbers, solidifying Labour's status as front-runner ahead of a national election next year.Labour leader Keir Starmer claimed his party was “redrawing the political map.” Labour candidate Sarah Edwards took Tamworth, where the Conservatives won by almost 20,000 votes in 2019, and Labour's Alistair Strathern took Mid-Bedfordshire by overturning a 25,000-vote Tory margin.John Curtice, a polling expert at the University of Strathclyde, said the “exceptional swings” to Labour could be compared to the collapse in Conservative support under Prime Minister John Major in the 1990s.“And we all know how that ended," he said — in a landslide 1997 election victory for Labour under Tony Blair.Others cautioned that turnout in Thursday's voting was low, and the elections were unusual because they replaced lawmakers who both resigned under a cloud.Tamworth legislator Chris Pincher quit after Parliament’s standards watchdog recommended he be suspended for “completely inappropriate” behavior after groping two men at a London private members’ club. Then-Prime Minister Boris Johnson’ s reluctance to sanction Pincher when the allegations emerged helped trigger Johnson’s ouster at the hands of his own party last year.Mid-Bedfordshire member of Parliament Nadine Dorries resigned over the treatment of Johnson and her own failure to be appointed to Parliament’s upper chamber, the House of Lords. Dorries is a strong ally of Johnson who has blamed Prime Minister Rishi Sunak for helping to topple the former leader.Conservative Party chairman Greg Hands blamed the losses on “legacy issues” and said people were “happy with the job Rishi Sunak is doing as prime minister.” The results add to pressure on the governing party, which has lost several byelections since Sunak took office just under a year ago. He replaced Liz Truss, who announced her resignation a year ago Friday after her plan for unfunded tax cuts sent financial markets into turmoil and rocked the economy.Truss spent just seven weeks in office after winning a party leadership contest to replace Boris Johnson, who quit after three years in office when scandals over money and ethics turned party lawmakers against him.Sunak steadied the economy but has not managed to boost the party’s rating in opinion polls, where it consistently lags between 10 and 20 points behind Labour. A national election must be called by the end of 2024.Friday's results confirm polls showing the Conservatives are losing support across the country, from affluent southern voters turned off by Brexit to working-class northern voters who switched from Labour in 2019 after Johnson promised to spread prosperity to long-neglected areas.。    Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。

Current article:http://www.lichuorenrenyitankanmeimu.cfd/mnerb/20260826/6636.xls

Published on:18:26:29